ストックスクリーナーアプリを入手
0.3012
12.26%
-0.0421
アフターアワーズ：
.30
-0.0012
-0.40%
Vivos Therapeutics Inc (VVOS) 最新ニュース
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance
Vivos Therapeutics stock falls 6% on second quarter revenue miss - Investing.com
Vivos Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Vivos Therapeutics posts strong Q2 2026 revenue growth - Investing.com Canada
Transcript : Vivos Therapeutics, Inc., Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vivos Therapeutics Q2 revenue up 35% YoY; gross margin expands to 57% - scanx.trade
Vivos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com - Investing.com UK
Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results - Quiver Quantitative
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update - Yahoo! Finance Canada
Vivos Therapeutics Inc (NASDAQ: VVOS) Share Price, VVOS Stock News, VVOS Share Price & Updates - Kalkine
Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics schedules Q2 2026 results, conference call - scanx.trade
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call - marketscreener.com
Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn - Stock Titan
Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices - TipRanks
Vivos Oral Appliance Shows Improvement in Insomnia Severity - sleepreviewmag.com
Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS) - Stock Titan
Vivos partners with Greenway Health to deploy AI platform - Investing.com
Vivos partners with Greenway Health to deploy AI platform By Investing.com - Investing.com Nigeria
Vivos Therapeutics Expands AI Workflow Partnership With Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada - Moomoo
Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada - Quiver Quantitative
Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada - Stock Titan
Vivos Therapeutics partners with Greenway Health for AI deployment - scanx.trade
Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology - Yahoo Finance
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology - The Manila Times
Vivos sleep apnea devices gain broader protection after new patent - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Trending Stocks Today | Vivos Therapeutics Soars 36.3% Post-Market - Moomoo
Vivos Therapeutics (VVOS) Edges Up 1.71% to $0.42 as Stock Tests Range Between $0.40 Support and $0.44 ResistanceCovered Call Trade - dars.gov.et
Vivos Therapeutics appoints Roman Franklin as new CFO - scanx.trade
Price to sales forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Price to book forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.390|Chg%:-0.013 - TradingKey
Vivos Therapeutics, Inc. Revenue Breakdown – NASDAQ:VVOS - TradingView
Vivos Therapeutics Inc (VVOS) Balance Sheet - TradingKey
Vivos Therapeutics Inc (VVOS) Income Statement - TradingKey
Vivos Therapeutics Inc (VVOS) Cash Flow - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.395|Chg%:+0.002 - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.304|Chg%:-0.039 - TradingKey
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vivos Therapeutics (VVOS) Holds Near Support as Micro-Cap Stock Shows Measured MovementVolatility Breakout Picks - dars.gov.et
Vivos Therapeutics (VVOS) Edges Higher, Testing Key Resistance Near $0.44Dynamic Hedging - dars.gov.et
Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts - Yahoo Finance
Vivos Therapeutics (VVOS) Holds Steady at $0.41, Support Level in FocusFear Greed Index - dars.gov.et
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Vivos Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
2.43%
大文字化:
|
ボリューム (24 時間):